ATS
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Personal Folders
Right arrow Download to citation manager
Right arrow Permission Requests
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Boehle, A. S.
Right arrow Articles by Dohrmann, P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Boehle, A. S.
Right arrow Articles by Dohrmann, P.
Related Collections
Right arrow Lung - transplantation

Ann Thorac Surg 2001;71:1657-1665
© 2001 The Society of Thoracic Surgeons

Original article: general thoracic

Combretastatin A-4 prodrug inhibits growth of human non–small cell lung cancer in a murine xenotransplant model

Arnd S. Boehle, MDa, Bence Sipos, MDc, Ursula Klicheb, Holger Kalthoff, PhDb, Peter Dohrmann, PhDa

a Department for General Surgery and Thoracic Surgery, Christian-Albrechts-University, Kiel, Germany
b Molecular Oncology Research Division, Christian-Albrechts-University, Kiel, Germany
c Department of Pathology, Christian-Albrechts-University, Kiel, Germany

Accepted for publication December 14, 2000.

Address reprint requests to Dr Boehle, Department of General Surgery and Thoracic Surgery, Christian-Albrechts-University, Arnold-Heller-Strasse 7, D-24105 Kiel, Germany
e-mail: boehle{at}surgery.uni-kiel.de

Background. Combretastatin A-4 prodrug (CA-4PD) has been identified as a potent antivascular agent in various rodent tumor models. The aim of this study was to investigate the effect of CA-4PD on human non–small cell lung cancer (NSCLC).

Methods. Cytostatic and cytotoxic effects of CA-4PD on selected NSCLC cells, Colo-699 and KNS-62, were studied in vitro. After subcutaneous xenotransplantation the effect of systemically administrated CA-4PD on tumor growth was investigated in vivo. A newly established orthotopic xenotransplant model was employed to estimate prolongation of survival after intrapulmonary tumor induction with secondary metastatic disease.

Results. In vitro, CA-4PD displayed a time and dose dependent antiproliferative effect on human lung cancer cells. In vivo, CA-4PD significantly delayed growth of subcutaneously induced lung cancer. This growth delay was translated into a prolongation of survival in the metastasizing orthotopic xenotransplant model.

Conclusions. In vitro CA-4PD inhibits proliferation of NSCLC cells, most likely by disruption of microtubule assembly. In vivo, systemic treatment inhibits growth of subcutaneously xenotransplanted tumors by an antivascular effect. In the case of metastasizing human lung cancer this translated into a prolongation of survival.




This article has been cited by other articles:


Home page
 Cancer Res.Home page
T. J. Kim, M. Ravoori, C. N. Landen, A. A. Kamat, L. Y. Han, C. Lu, Y. G. Lin, W. M. Merritt, N. Jennings, W. A. Spannuth, et al.
Antitumor and Antivascular Effects of AVE8062 in Ovarian Carcinoma
Cancer Res., October 1, 2007; 67(19): 9337 - 9345.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
H.-L. Lin, S.-H. Chiou, C.-W. Wu, W.-B. Lin, L.-H. Chen, Y.-P. Yang, M.-L. Tsai, Y.-H. Uen, J.-P. Liou, and C.-W. Chi
Combretastatin A4-Induced Differential Cytotoxicity and Reduced Metastatic Ability by Inhibition of AKT Function in Human Gastric Cancer Cells
J. Pharmacol. Exp. Ther., October 1, 2007; 323(1): 365 - 373.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
P. Thomson, M. A. Naylor, S. A. Everett, M. R.L. Stratford, G. Lewis, S. Hill, K. B. Patel, P. Wardman, and P. D. Davis
Synthesis and biological properties of bioreductively targeted nitrothienyl prodrugs of combretastatin A-4.
Mol. Cancer Ther., November 1, 2006; 5(11): 2886 - 2894.
[Abstract] [Full Text] [PDF]

Home page
 IOVSHome page
E. Escalona-Benz, M.-E. Jockovich, T. G. Murray, B. Hayden, E. Hernandez, W. Feuer, and J. J. Windle
Combretastatin A-4 Prodrug in the Treatment of a Murine Model of Retinoblastoma
Invest. Ophthalmol. Vis. Sci., January 1, 2005; 46(1): 8 - 11.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
Y. Zou, H. Fu, S. Ghosh, D. Farquhar, and J. Klostergaard
Antitumor Activity of Hydrophilic Paclitaxel Copolymer Prodrug Using Locoregional Delivery in Human Orthotopic Non-Small Cell Lung Cancer Xenograft Models
Clin. Cancer Res., November 1, 2004; 10(21): 7382 - 7391.
[Abstract] [Full Text] [PDF]

Home page
 Eur Respir JHome page
C.S. Brock and S.M. Lee
Anti-angiogenic strategies and vascular targeting in the treatment of lung cancer
Eur. Respir. J., March 1, 2002; 19(3): 557 - 570.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Pathol.Home page
J. Griggs, J. N. Skepper, G. A. Smith, K. M. Brindle, J. C. Metcalfe, and R. Hesketh
Inhibition of Proliferative Retinopathy by the Anti-Vascular Agent Combretastatin-A4
Am. J. Pathol., March 1, 2002; 160(3): 1097 - 1103.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
ANN THORAC SURG ASIAN CARDIOVASC THORAC ANN EUR J CARDIOTHORAC SURG
J THORAC CARDIOVASC SURG ICVTS ALL CTSNet JOURNALS
Copyright © 2001 by The Society of Thoracic Surgeons.